Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens

Author(s): Suidong Ouyang, Ji-Ming Feng.

Journal Name: Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)

Volume 3 , Issue 1 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Type I diabetes (T1D) is an organ-specific autoimmune disease that targets on the destruction of insulin-producing pancreatic β cells. Many strategies, including immunosuppressive and antigen-specific immunoregulatory therapies, have been per- formed in animal models and in the clinic to prevent and treat T1D. Among them, induction of regulatory T cells (Treg) specific to β cell-associated autoantigens (BAA) for T1D therapy provides several advantages, including specificity and lasting effica- cy in controlling unrestricted autoimmunity. In this review, we discuss the progression of applying autoantigen-specific Treg cells in treating T1D, hoping to provide some useful information for future clinicians to develop more effective and safe antigen- specific immunoregulatory therapies on T1D treatment.

Keywords: Autoantigen, β Cell, immunoregulatory therapies, organ-specific autoimmune disease, T regulatory cells, type I diabetes.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 3
ISSUE: 1
Year: 2016
Page: [47 - 53]
Pages: 7
DOI: 10.2174/2212707003666160902145753

Article Metrics

PDF: 18